Ascendis Pharma Reports Second Quarter 2026 Financial Results

Ascendis Pharma Reports Strong Q2 2026 Financials and Pipeline Progress

Ascendis Pharma A/S reported strong financial results for the second quarter ended June 30, 2026, with total product revenue reaching €315 million, marking a 105% year-over-year increase. This growth was driven by YORVIPATH® revenue of €252 million, SKYTROFA® revenue of €55 million, and initial YUVIWEL® revenue of €8 million. The company also provided significant pipeline updates, including long-term Phase 2 and 3 data for YORVIPATH, Week 78 data from the Phase 2 COACH Trial for TransCon CNP + TransCon hGH combination therapy, and the completion of target enrollment for the pivotal reACHin Trial for YUVIWEL. Ascendis Pharma achieved an operating profit of €220 million and a net profit of €207 million for the quarter, further bolstered by the sale of a Rare Pediatric Disease Priority Review Voucher for €158 million.

• Ascendis Pharma demonstrated robust commercial growth in Q2 2026, with total product revenue soaring to €315 million, a 105% increase year-over-year. This performance was primarily fueled by strong and consistent patient demand for YORVIPATH®, which generated €252 million, and SKYTROFA®, contributing €55 million. The recently launched YUVIWEL® also began contributing with €8 million in revenue and achieved over 220 unique patient enrollments in the U.S. through July 31, 2026.
• The company advanced its pipeline with significant clinical data and trial milestones across its rare endocrine disease portfolio. Long-term Phase 2 PaTH Forward (5-year) and Phase 3 PaTHway (3.5-year) data for YORVIPATH® in hypoparathyroidism showed sustained efficacy and safety. For YUVIWEL®, target enrollment was completed for the pivotal reACHin Trial in infants with achondroplasia, supporting future regulatory filings, and a Phase 3 trial for hypochondroplasia is anticipated to begin in the second half of the year.
• Ascendis Pharma reported strong financial profitability and progress in its combination therapy programs. The company achieved an operating profit of €220 million and a net profit of €207 million for Q2 2026. Additionally, Week 78 data from the Phase 2 COACH Trial for TransCon CNP and TransCon hGH combination therapy in pediatric achondroplasia showed sustained unprecedented efficacy with no compromise to safety, with all 21 enrolled children completing treatment and remaining on therapy.

YORVIPATH's Sustained Efficacy and Safety in Hypoparathyroidism

Three recent clinical studies have substantially advanced the evidence base for hormone replacement approaches in hypoparathyroidism. The PaTHway Trial, a Phase 3, 26-week study, evaluated TransCon PTH (palopegteriparatide) administered once daily. The intervention demonstrated compelling efficacy: 79% of treated participants (vs. 5% on placebo) met the composite primary efficacy endpoint (p < 0.0001), and 93% achieved independence from conventional therapy. Significant improvements were observed across all key secondary HPES domain scores (all p < 0.01) and in the SF-36 Physical Functioning subscale (p = 0.0347), with mean 24-hour urinary calcium normalised. From a safety standpoint, 82% of TransCon PTH-treated participants experienced adverse events, the majority of which were mild to moderate in severity; notably, no study drug-related withdrawals occurred, supporting an overall favourable tolerability profile.

A retrospective cohort study examining five-year outcomes with recombinant parathyroid hormone (1-84) [rhPTH(1-84)] pooled data from the REPLACE, RELAY, RACE, and HEXT clinical trials, encompassing 72 rhPTH(1-84)-treated adults and 176 controls. The primary finding was a meaningful preservation of renal function: eGFR remained stable in the rhPTH(1-84) cohort over five years, with a projected gain of 1.21 mL/min/1.73 m² from baseline, whereas the control cohort experienced an eGFR decline of 1.67 mL/min/1.73 m² per year — a cumulative five-year loss of 10.36 mL/min/1.73 m². The between-cohort difference in eGFR slopes was 1.37 mL/min/1.73 m² per year (95% CI: 0.62–2.13; p < 0.001). Additionally, rhPTH(1-84) therapy was associated with at least a 50% reduction in exogenous calcium and active vitamin D requirements, alongside decreased 24-hour urinary calcium excretion, demonstrating both conventional therapy-sparing effects and renal protective potential.

An open-label, 16-week study evaluated oral hPTH(1-34) tablets (0.75 mg human PTH(1-34) acetate, administered four times daily) in 19 enrolled subjects, 15 of whom completed the study per protocol. Treatment resulted in a median 42% reduction in exogenous calcium dose from baseline (p = .001), with albumin-adjusted serum calcium maintained above the hypoparathyroidism target threshold of 7.5 mg/dL throughout the study period. Serum phosphate declined rapidly — by 23% as early as two hours post-first dose (p = .0003) — and remained within the normal range, while a 21% decrease in 24-hour urinary calcium excretion was observed between the first and final treatment days (p = .07). A small but statistically significant improvement in quality of life (5%; p = .03) was also recorded. The safety profile was notably clean: only four possible drug-related, non-serious adverse events were reported over the full 16-week duration, all attributable to a single patient, reinforcing the tolerability of the oral formulation.

Addressing Unmet Needs in Hypoparathyroidism Treatment

Hypoparathyroidism remains a condition with substantial unmet medical need, as conventional calcium and active vitamin D supplementation fails to fully restore physiological mineral homeostasis and is associated with a considerable long-term complication burden. Emerging clinical evidence continues to highlight specific patient populations and therapeutic gaps that are driving the development of novel treatment strategies.

• Limitations of conventional therapy: Standard treatment with calcium and active vitamin D is associated with fluctuating serum calcium levels, hypercalciuria, high pill burden, and diminished quality of life. Even patients on stable regimens may continue to experience symptomatic burden, underscoring the failure of conventional approaches to replicate the nuanced regulatory role of parathyroid hormone.

• Renal complication risk: Chronic hypoparathyroidism managed with traditional supplementation carries significant long-term renal risk, including nephrocalcinosis, nephrolithiasis, and progressive renal impairment. Obesity has been independently associated with chronic kidney disease (CKD) in this population, further compounding renal vulnerability and highlighting the need for treatment options with a more favorable renal safety profile.

• Quality of life impairments: Across published studies, approximately 87% reported statistically significantly lower quality of life scores in at least one domain compared to normative populations or controls. Commonly reported symptoms include paresthesia, daily fatigue, and memory alterations, with postsurgical hypoparathyroid patients also demonstrating limited treatment adherence alongside impaired quality of life.

• Targeted patient populations: The primary population under therapeutic focus is adults with chronic hypoparathyroidism, estimated at 70,000–90,000 individuals in the United States. The majority of cases are postsurgical in origin, with remaining cases attributable to autoimmune, genetic, infiltrative, or metabolic causes. Patients with compromised renal function represent a particularly critical subgroup, for whom treatments with reduced renal strain are an urgent priority.

YORVIPATH's Impact on the Hypoparathyroidism Treatment Landscape

Over the past five years, the treatment landscape for hypoparathyroidism has undergone substantial evolution, driven by clinical trial data supporting novel PTH replacement strategies alongside continued recognition of the limitations inherent to conventional therapy. Standard first-line management — encompassing oral calcium supplementation, active vitamin D (calcitriol), correction of vitamin D inadequacy, and normalization of serum magnesium — remains guideline-endorsed but carries well-documented drawbacks, including serum calcium fluctuations, hypercalciuria, progressive renal impairment, elevated pill burden, and diminished quality of life. These limitations have reinforced the clinical rationale for pursuing physiologic PTH replacement as a more durable therapeutic approach.

Two PTH replacement therapies have defined the recent clinical narrative. Recombinant human PTH(1-84) [rhPTH(1-84)] demonstrated sustained biochemical benefit in a 6-year open-label extension study across 12 US centers (n = 49 adults), maintaining mean albumin-adjusted serum calcium within 2.00–2.25 mmol/L throughout 72 months. Oral calcium supplementation was reduced by 45% and calcitriol by 74%, while 54% of patients who were hypercalciuric at baseline achieved normocalciuria by month 72. Adverse events attributed to rhPTH(1-84) were reported in 51% of patients, with nearly all graded mild to moderate. More recently, palopegteriparatide (TransCon PTH) — a prodrug engineered for sustained PTH(1-34) release over 24 hours — demonstrated normocalcemia maintenance without conventional therapy in a Phase 3 study, alongside reductions in urinary calcium and measurable quality-of-life improvements. Now approved in Europe and positioned within updated international recommendations, palopegteriparatide represents the most clinically significant advancement in this space to date.

The field is further informed by evolving guideline frameworks and an active pipeline. Best practice recommendations ratified at the 2024 Parathyroid Summit (Boston, May 2024) build upon the 2022 international hypoparathyroidism guidelines and three systematic reviews, formally incorporating palopegteriparatide's positioning based on recent trial data and expert consensus. These recommendations reinforce individualized care pathways, emphasize the role of genetic/DNA analysis in nonsurgical hypoparathyroidism diagnosis, and affirm PTH or PTH analogue therapy where conventional management proves inadequate or intolerable. Looking ahead, the long-acting PTH analogue eneboparatide is currently in Phase 3 evaluation, and the calcilytic agent encaleret is under investigation specifically for autosomal dominant hypocalcemia type 1 — collectively signaling continued momentum toward more targeted, mechanism-driven management of this historically undertreated condition.